Mirae Asset Global Investments Co., Ltd. Arcutis Biotherapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $22.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,228 shares of ARQT stock, worth $43,971. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,228
Previous 3,456
22.34%
Holding current value
$43,971
Previous $32,000
21.88%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ARQT
# of Institutions
195Shares Held
128MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.7MShares$121 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$104 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$102 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$91.4 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$89.7 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $626M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...